EligibleTrials

A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease

Recruiting · NCT05413655 · Interventional (participants receive a specific treatment) · Lead sponsor: Excelsior

View the official record on ClinicalTrials.gov →
Alzheimer's disease

Interventions studied

EX039Placebo

What this trial is about

This is a phase 2, randomized, double-blind, placebo-controlled study of oral EX039 as add-on to Acetylcholine Esterase Inhibitors in subjects with mild Alzheimer's disease.

Who can take part

Age range
50 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.